Spevatamig

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Spevatamig
www.ebi.ac.uk

  • h gamma1 heavy chain anti cd47 1 444 g1v92 1 vh e44 ch1 e77 vh e44 homo sapiens ighv1 46 01 87 6 q44 e 39 ighd ighj4 01 100 cdr imgt 8 8 7 26 33 51 58 97 103 1 114 homo sapiens ighg1 01 g1m17 1 ch1 k120 ch3 d12 l14 ch1 e77 g1v93 ch1 c12 g1v37 h s5 g1v74 ch3 c10 g1v32 ch3 w22 knob ch1 k12 c 130 g77 e 163 k120 211 115 212 hinge 1 15 c5 s 217 213 227 ch2 228 337 ch3 s10 c 351 d12 353 l14 355 t22 w 363 338 442 chs 443 444 115 444 130 209 disulfide with l kappa light chain anti cd47 1 214 kv92 1 v kappa k44 c kappa k3 v kappa k44 homo sapiens igkv3 20 01 83 3 q44 k 38 igkj1 01 91 7 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 98 1 km3 a45 1 v101 k3 kcv37 c121 s126 c kappa s3 k 114 a45 1 153 v101 191 f121 c 209 c126 s 214 108 214 h gamma1 heavy chain anti cldn18 1 449 g1v92 2 vh k44 ch1 k77 vh k44 homo sapiens ighv3 48 01 87 8 q44 k 39 ighd ighj4 01 92 9 cdr imgt 8 8 12 26 33 51 58 97 108 1 119 homo sapiens ighg1 01 g1m17 1 ch1 k120 ch3 d12 l14 ch1 k77 g1v75 ch3 c5 g1v33 ch3 s22 a24 v86 hole ch1 g77 k 168 k120 216 120 217 hinge 1 15 218 232 ch2 233 342 ch3 y5 c 351 d12 358 l14 360 t22 s 368 l24 a 370 y86 v 409 343 447 chs 448 449 120 449 222 220 disulfide with l kappa light chain anti cldn18 1 220 kv92 2 v kappa e44 c kappa e3 v kappa e44 musmus homsap mus musculus igkv8 19 01 79 2 q44 e 44 igkj2 03 81 8 s120 q 106 l124 v 110 homo sapiens igkv1 39 01 78 2 q44 e 44 igkj1 01 100 cdr imgt 12 3 9 27 38 56 58 95 103 1 113 homo sapiens igkc 01 99 1 km3 a45 1 v101 e3 c kappa s3 e 120 a45 1 159 v101 197 114 220 dimer 223 228 226 231 351 351 trisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
  • H-gamma1 heavy chain anti-CD47 (1-444), G1v92-1 VH E44, CH1 E77 [VH E44 (Homo sapiens IGHV1-46*01 (87.6%) Q44>E (39') -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, CH1 E77, G1v93 CH1 C12, G1v37 h S5, G1v74 CH3 C10, G1v32 CH3 W22 (knob) (CH1 K12>C (130), G77>E (163), K120 (211) (115-212), hinge 1-15 C5>S (217) (213-227), CH2 (228-337), CH3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), CHS (443-444)) (115-444)], (130-209')- disulfide with L-kappa light chain anti-CD47 (1'-214') Kv92-1 V-KAPPA K44, C-KAPPA K3 [V-KAPPA K44 (Homo sapiens IGKV3-20*01 (83.3%) Q44>K (38') -IGKJ1*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101, K3, KCv37 C121, S126 (C-KAPPA S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-gamma1 heavy chain anti-CLDN18 (1-449), G1v92-2 VH K44, CH1 K77 [VH K44 (Homo sapiens IGHV3-48*01 (87.8%) Q44>K (39'') -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, CH1 K77, G1v75 CH3 C5, G1v33 CH3 S22, A24, V86 (hole) (CH1 G77>K (168''), K120 (216'') (120''-217''), hinge 1-15 (218''-232''), CH2 (233''-342''), CH3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-220''')-disulfide with L-kappa light chain anti-CLDN18 (1'''-220''') Kv92-2 V-KAPPA E44, C-KAPPA E3 [V-KAPPA E44 (Musmus/Homsap (Mus musculus IGKV8-19*01 (79.2%) Q44>E (44''') -IGKJ2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo sapiens IGKV1-39*01 (78.2%) Q44>E (44''') -IGKJ1*01 (100%), CDR -IMGT [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo sapiens IGKC*01 (99.1%) Km3 A45.1, V101, E3 (C-KAPPA S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; dimer (223-228'':226-231'':351-351'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
  • immunoglobulin (H-gamma1_L-kappa)_(H-gamma1_L-kappa), anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J) isoform 2], bispecific
  • Immunoglobulin G1 [168-lysine,351-cysteine,368-serine,370-alanine,409-valine], anti-(human claudin CLDN18.2) (human-Mus musculus monoclonal PT886 γ1-chain), disulfide with [120-glutamic acid] human-Mus musculus monoclonal PT886 κ-chain, (228→223′),(231→226′),(351→351′)-tris(disulfide) with immunoglobulin G1 [130-cysteine,163-glutamic acid,217-serine,351-cysteine,363-tryptophan] anti-(human CD47 antigen) (human-Mus musculus monoclonal PT886 γ1-chain) disulfide with [114-lysine,209-cysteine,214-serine] human-Mus musculus monoclonal PT886 κ-chain
  • immunoglobulin g1 168 lysine 351 cysteine 368 serine 370 alanine 409 valine anti human claudin cldn18 2 human mus musculus monoclonal pt886 γ1 chain disulfide with 120 glutamic acid human mus musculus monoclonal pt886 κ chain 228 223 231 226 351 351 tris disulfide with immunoglobulin g1 130 cysteine 163 glutamic acid 217 serine 351 cysteine 363 tryptophan anti human cd47 antigen human mus musculus monoclonal pt886 γ1 chain disulfide with 114 lysine 209 cysteine 214 serine human mus musculus monoclonal pt886 κ chain
  • immunoglobulin h gamma1 l kappa h gamma1 l kappa anti homo sapiens cd47 cd47 molecule integrin associated protein iap mer6 oa3 and anti homo sapiens cldn18 claudin 18 claudin 18 sftpj surfactant associated protein j isoform 2 bispecific
  • pt 886
  • PT-886
  • pt886
  • PT886
  • spevatamig
  • Spevatamig
  • Spevatamig (PT886)
  • spevatamig [INN]
  • SPEVATAMIG [USAN]
  • Spevatamig [WHO-DD]
  • spevatamig inn
  • spevatamig pt886
  • spevatamig usan
  • spevatamig who dd

CAS registry numbers
  • 2928515-36-8
ChEMBL ID
CHEMBL6068300
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • LVB74L4PM2

First in class
No
Orphan designation
No

Drug name stem
-mig

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0003219
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005036
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005184
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain: H-gammaanti-CD7(knob)(H)
    Type
    Protein
    Sequence
    QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVREAPGQGLEWIGNIDPSDSETHYAQKFQGRVTLTVDKSTSTVYMELSSLRSEDTAVYYCAGTDLAYWGQGTLVTVSSASTKGPSVFPLAPSSCSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSEVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Light chain: L-kappaanti-CLDN8(L''')
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCKSSLSLLNSGNQKNYLTWYQEKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYSCQNAYSYPLTFGQGTKVEIKRTVAAPEVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    294 $ 299''
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-94''' $ 130-209' $ 134'-194' $ 140'''-200''' $ 141-197 $ 146''-202'' $ 222''-220''' $ 223-228'' $ 226-231'' $ 258-318 $ 263''-323'' $ 351-351'' $ 364-422 $ 369''-427''
  • Component
    Heavy chain: H-gammaanti-CLDN8(hole)(H'')
    Type
    Protein
    Sequence
    EVQLVESGGGLVQPGGSLRLSCAASGFIFSSFGMHWVRKAPGKGLEWVAYISSGRSTMYYADSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARGGFYGNSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Light chain: L-kappaanti-CD7(L')
    Type
    Protein
    Sequence
    EIVLTQSPGTLSLSPGERATLSCHASQNINVWLSWYQKKPGQAPRLLIYKASNLHTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGQSYPFTFGQGTKVEIKRTVAAPKVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSCNRGES

Related records

Trials (1)

In development for (4)